RSS
Home
FDA warns that Byetta can lead to kidney problems
Print
Email
RSS
Subscribe
Today the FDA indicated that the safety label of Byetta would be modified to include potential kidney problems including possible kidney failure. According to the FDA website "From April 2005 through October 2008, the FDA received 78 reports of problems with kidney function in patients using Byetta." Now, keep in mind here that 7 million prescriptions were issued during this time so this represents about 1 in 100,000 people being affected.
Byetta is a drug taken to assist in the processing of blood sugar. it is one of a family of drugs known as incretin based therapies. (To learn more about incretins click here). One of the side effects of Byetta as well as other incretin based therapies is vomiting. This is thought to play a role in kidney dysfunction.
Back in February, Diabetes Care published a short report on 4 patients who had suffered serious kidney damage from Byetta therapy and this may serve as an example of what has happened to the others. All four presented with vomiting and decreased fluid intake. Because of their diabetes induced hypertension they were on ACE inhibitors and diuretics. All suffered kidney failure within 2 - 9 months of initiating Byetta therapy and were taken off the treatment upon diagnosis. All recovered some kidney function although recovery was not complete in 3 out of the 4 patients.
The opinion of the authors was that the combination of vomiting (fluid loss), decreased fluid intake, ACE inhibitors, and diuretics provided too much of a stress on the kidney. They did point to a study which shows that the incretin GLP-1 was shown to perhaps decrease kidney function in healthy subjects however it is not known if Byetta does this or not.
In summary, if you have kidney problems you may not want to take Byetta. If you do take Byetta, be sure to keep your fluid levels up by drinking sufficient amounts of water. As with all therapies consult with your doctor before making any changes.
If you want to know more about diabetes and a health diabetes lifestyle sample A Sweet Life, the magazine for the healthy diabetic. http://aweetlife.org.
Related Articles:
Add a Comment
- Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis.
- Unmasking of a protective tumor necrosis factor receptor I-mediated signal in the collagen-induced arthritis model.
- Loss of a gimap/ian gene leads to activation of NF-kappaB through a MAPK-dependent pathway.
- AIRE recruits multiple transcriptional components to specific genomic regions through tethering to nuclear matrix.
- Partial activation precedes apoptotic death in T cells harboring an IAN gene mutation.
- Increased NF-kappa B activity in B cells and bone marrow-derived dendritic cells from NOD mice.
- The identification of a novel T cell activation state controlled by a diabetogenic gene.
